Abstract:Alcohol-associated hepatitis (AH) is associated with increased short-term mortality in the presence of infections and rapid onset of extrahepatic organ failure driven by intestinal dysbiosis. [ 1 ] Deleterious modifications of the gut microbiota (GM) which include bacteria, fungi, and viral groups in the presence of alcohol are well documented across multiple studies globally. [ 2 ] Gut microbiota contributes to individual susceptibility to alcohol-related liver disease (ALD) and AH through detrimental changes to immune signaling, functional metabolism, and the gut–brain axis. [ 3 ] Specific bacterial taxa have been shown to affect the promotion, progression, and clinical events associated with ALD and AH. For example, in the presence of alcohol, pathogenic bacteria, such as Acinetobacter baumannii enhance their virulence. Alcohol use reduces bacterial diversity, decreases the abundance of beneficial Bacteroidetes, and increases that of pathogenic Proteobacteria, as demonstrated by a significant decrease in Ruminococcaceae and an increase in both Lachnospiraceae and Enterobacteriaceae. [ 4 , 5 ] Alcohol-induced GM dysbiosis leads to liver damage owing to the proliferation of harmful microorganisms that produce exotoxins. One such exotoxin, cytolysin, secreted by Enterococcus faecalis , can directly harm hepatocytes. A higher presence of cytolysin-positive Enterococcus faecalis correlates with greater severity of liver disease and elevated mortality rates in patients with AH. [ 6 ] Specific GM, their interactions, and metabolites are associated with complications of AH and the corresponding treatment outcomes. [ 7 ] Similarly, fungal dysbiosis and fungal metabolites affect the severity of AH. The burgeoning field of research on fungal dysbiosis and proliferation of specific fungal species in ALD has revealed significant findings. Elevated serum levels of anti- Saccharomyces cerevisiae immunoglobulin G antibodies, which indicate a systemic immune response to fungi and their byproducts, are observed in patients with alcohol use disorder and ALD. In patients with AH, heightened serum anti- Saccharomyces cerevisiae immunoglobulin G antibodies levels are associated with increased mortality. Additionally, a higher relative abundance of specific fungal species, such as Candida albicans and Malassezia restricta in the gut, correlates with more severe liver injury and increased mortality in ALD patients. [ 8–10 ] Preliminary studies have shown that patients with ALD and AH can benefit from GM modulation. Clinical trials have explored the use of fecal microbiota transplantation (FMT) to alter the gut microbiome of patients with AH. Studies have demonstrated that AH patients who received FMT from healthy donors exhibited lower rates of alcohol relapse, infections, or hospitalizations; higher rates of resolution of hepatic encephalopathy and ascites; and improved survival in both the short and long term when compared to standard medical care, including pentoxifylline therapy. [ 11–13 ] Another randomized controlled study included 120 patients with AH who received either prednisolone or a healthy donor FMT. Patients receiving FMT had better 90-day survival rates and a reduced incidence of infections compared to those receiving prednisolone. [ 14 ] Probiotics have been shown to improve clinical outcomes in alcohol-associated cirrhosis, and foundational evidence supports their positive effects on GM. Preliminary evidence also supports the beneficial effects of probiotic therapy on GM in AH. [ 15 , 16 ] Nonetheless, the validated and replicated benefits of probiotic therapy and their impact on survival in the context of GM modulation remain unknown. Similarly, probiotic therapy-related modifications within fungal communities, fungal–bacterial interactions, and associated clinical outcomes in AH are enigmatic. We aimed to study the clinical outcomes and GM changes in AH patients receiving high-dose probiotic infusion (HDPI) compared to corticosteroid therapy (CST). Additionally, survival outcomes compared with matched patients undergoing healthy donor FMT were also analyzed. We also studied mycobiome (fungal) community changes and their interactions among patients with AH in the context of HDPI and CST therapies.

G‐CSF—In Patients With Severe Alcohol‐Associated Hepatitis: A Real‐World Experience

Granulocyte colony stimulating factor improves Prednisolone responsiveness and 90-day survival in steroid eligible severe Alcohol associated Hepatitis: The GPreAH Study a randomized trial

Granulocyte Colony-Stimulating Factor in Severe Alcoholic Hepatitis: A Randomized Pilot Study

Granulocyte Colony-Stimulating Factor Plus Pentoxifylline Increases Short-Term Survival in Patients with Severe Alcoholic Hepatitis: a Network Meta-Analysis.

Granulocyte-monocyte/macrophage apheresis for steroid-nonresponsive or steroid-intolerant severe alcohol-associated hepatitis: A pilot study

Survival benefit from corticosteroids in severe alcohol-associated hepatitis attributed to clinical and treatment differences in a large multicenter cohort

Determinants of long-term outcome in severe alcoholic hepatitis

Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study

Granulocyte colony‐stimulating factor attenuates liver damage by M2 macrophage polarization and hepatocyte proliferation in alcoholic hepatitis in mice

Expedited liver transplantation as first‐line therapy for severe alcohol hepatitis: ELFSAH; deferring corticosteroids in the sickest subset of patients

The Impact of Steroid Responder Status on Long-Term Outcomes in Critically Ill Patients With Acute Respiratory Distress Syndrome Receiving High-Dose Glucocorticoids

The efficacy and safety of granulocyte colony-stimulating factor in the treatment of acute-on-chronic liver failure: A systematic review and meta-analysis

Impact of Karnofsky performance status on outcomes of patients with severe alcohol‐associated hepatitis: a propensity‐matched analysis

Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial

S1924 Impact of Granulocyte Colony Stimulating Factor on the Survival of Patients With Decompensated Cirrhosis and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-analysis

Clinical outcomes and associated bacterial and fungal microbiota changes after high dose probiotic therapy for severe alcohol-associated hepatitis: An observational study

GCSF Deficiency Attenuates Nonalcoholic Fatty Liver Disease Through Regulating GCSFR-SOCS3-JAK-STAT3 Pathway and Immune Cells Infiltration.

O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY

G-CSF increases calprotectin expression, liver damage and neuroinflammation in a murine model of alcohol-induced ACLF

Therapeutic Effect and Safety of Granulocyte Colony-Stimulating Factor Therapy for Acute-On-Chronic Liver Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

The impact of G-CSF on mouse immune cells in alcoholic liver disease, focusing on variations in T cells and their subsets